Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Does state "The purchaser may use the product for its internal in vitro research and evaluation of the reagent for use as a
COVID-19 SARS-CoV-2 antigen diagnostic test."
https://drive.google.com/file/d/1OTqkfkOpkNrMTLBBxtGwhLcwC096KvM4/view
At the end of the paper, reference (1) states:
[1] Carter LJ, Garner LV, Smoot JW, Li Y, Zhou Q, Saveson CJ, Sasso JM, Gregg AC, Soares DJ, Beskid TR, Jervey SR, Liu C
(2020). ACS Cent. Sci. 6: 591-605.
Notice 2020 in there, 5 years after 2015?
Refers to SARS
Don't think Covid 19 existed in 2015?!
That paper is from 29/9/2015
Sorry, Just being pedantic on updating versions of documents.
It is a massive step forward + talk of Sona also. Great news at the end of a difficult day.
Not a great start.
The Adeptrix product data sheet dated 15/9/2020, includes an updated reference to a document dated 29/9/2020?
We're not exactly speeding - haha. The BAMS test needs to complete validation in UK and Stateside and will no doubt receive FDA approval too in due course.
So basically we’re either getting a speeding ticket or an RNS tomorrow ?
The product details for the Adeptrix BAMS assay references the Bruker Application Note published 29 Sept - see bottom of https://drive.google.com/file/d/1OTqkfkOpkNrMTLBBxtGwhLcwC096KvM4/view
I think we have a product on the market
Sorry - Bruker not Brucker.
The Brucker paper is dated as "Modified" 28th September
Well, now we know where Sir Al got his ‘fingerprint’ from. Figure 4 in the link. Nice find! RUO, but now available for sale, progress indeed.
The product has been validated using recombinant SARS-CoV-2 S1 spike viral glycoprotein containing 688 amino
acid residues including the sequence [16-685] from S glycoprotein followed by a tag containing 10 consecutive His
residues at the C-terminus. Eluted intact S1 glycoprotein was analyzed on Bruker Daltonics rapifleX, microflex smart
LS and microflex LT MALDI TOF MS instruments in linear mode using the instrument method with the mass range
expanded to 10-300 kDa.
Spike reagent product sheet
https://drive.google.com/file/d/1OTqkfkOpkNrMTLBBxtGwhLcwC096KvM4/view
Yes, Adeptrix have partnered with Bruker. This is actually huge news as route to market is now cleared and the volume of Bruker installed mass spec machines, globally, is huge.....
At 120 usd per 8 reactions (15 usd per reaction) we can start to forecast revenue. Each machine can run >1000 reactions per day...
Actually I agree with you now Wiggly, they could be making the mass spectrometer
https://www.bruker.com/products.html
That finger print in the link looks familiar - was that not the same picture used in the presentation.
Wiggly-it is an academic paper only to inform the profession. Adeptrix is marketing the test as said in the presentation 22.00-25.30 https://avacta.com/interim-results-for-the-period-ended-30-june-2020-webinar-presentation/
Al did say Solid progress had been made in securing a commercial partnership for BAMS and news would be shared in weeks
Wiggy, I think that is highly likely!
From the ELISA test results, we know that that product using the same Affimers for detection as BAMS has the best S&S yet seen on any Covid19 test, for the original SARS-COV2 and now the latest mutation. Given what we were told yesterday the LFD which surely must be suing the same Affimers as well, which is going to be used to test if a person not only has the Virus, but most critically is contagious! That is the most important factor for the public out in the field. There are 3 symptoms which are clear to indicate the likelihood of having the virus, but if we are to stop the spread, it is vital to know if we are going to be spreading it during the infectious period. That is the purpose of our test.
Yes we need it now, but the work on it has be surely most carefully calculated to ensure we offer the most important test for infield application.
There is no sign of it going away or becoming weaker, only becoming more infectious and that is a huge concern. Nobody knows what pathway it will go or who it will effect us when the water gets much colder and we are less able to spend time outside.
On the link, you will see that the graphical chart is on that presentation as was used in the Avacta one yesterday, look at slide 22. So we can be sure Avacta are in a working partnership with Broker already.
I am not selling here, only buying, I think Avacta are set to bring the most important tests to market, which will compliment other tests already available. I also think Avacta will not have any issue selling them and they will most likely never need to use MEDUSA19! I actually think AS should walk away from that partnership as it will not be required.
I am pleased we have a US broker and I am sure that is step one in the road to a dual listing on the NASDAQ. If that happens as I have pointed out before, we will need to move onto the FTSE. Those events will be highly significant and if it is Q1 2021, that could be a perfect time. We are likely to see orders like the fantastic one announced by Novacyt today.
All investors need is patience and this will come to those who wait.
Cheers, Rich
The rapifleX is the most advanced MALDI TOF/TOF system on the market today and it is also the most adaptable.
Whether you are looking at top-down sequencing for Biotherapeutics and Biosimilars, glycan structure analysis and confirmation, and localization or disulfide/scrambling/ trisulfide bond determination, the rapifleX is the best instrument for the job.
The system combines state-of-the-art technology with advanced informatics into a system that gives you speed, robustness, versatility and confidence.
MALDI-TOF/TOF for every application and every market
Bruker has a long history of helping life scientists meet their toughest laboratory challenges. We provide the innovative MALDI TOF and MALDI TOF/TOF mass spectrometry systems that you rely on to accelerate your research.
The rapifleX is the latest example of Bruker’s dedication to developing and delivering innovative MALDI-TOF analysis technologies.
Now you can make the best decision in the shortest amount of time. In summary, the new Bruker rapifleX MALDI-TOF system represents a paradigm shift in terms of productivity, cost of ownership and ease of use.
The Bruker rapifleX platform offers a complete characterization system with unprecedented speed of analysis and performance.
09/2020 page 6 bottom right.
At the end - For Research Use Only. Not for Use in Clinical Diagnostic Procedures.